Investigators have suspected that there isn’t much advantage to renovascular angioplasty and stenting in atherosclerosis, but their studies haven’t had the statistical power to prove that point. A new bit of research in this week’s New England Journal of Medicine may have hit the mark. We’ve got an interview with two of the principals of the ASTRAL study (that’s their acronym for Angioplasty and Stenting for Renal Artery Lesions). Dr. Philip Kalra, the nephrology lead, and Dr. Jonathan Moss, the radiology lead, kin...
Investigators have suspected that there isn’t much advantage to renovascular angioplasty and stenting in atherosclerosis, but their studies haven’t had the statistical power to prove that point. A new bit of research in this week’s New England Journal of Medicine may have hit the mark. We’ve got an interview with two of the principals of the ASTRAL study (that’s their acronym for Angioplasty and Stenting for Renal Artery Lesions). Dr. Philip Kalra, the nephrology lead, and Dr. Jonathan Moss, the radiology lead, kindly agreed to the conversation, which I think you’ll find of interest.
Reach us with your comments and suggestions at jelia@jwatch.org, or call 1-617-440-4374.
This edition’s links:
Interview link–
- No Clinical Benefits of Revascularization in Atherosclerotic Renal Arteries
News links–
- H1N1 Update: Estimates of Flu’s Toll; Seasonal Vaccine Not Effective Against 2009 H1N1
- Prone Position for Acute Respiratory Distress Syndrome Doesn’t Boost Survival
The post Podcast 65: A conversation about the utility of renovascular angioplasty in the face of atherosclerosis first appeared on Clinical Conversations.
View more